Genomic sequencing remains a relatively early stage market, and expanding sequencing indications, including the nascent liquid biopsy applications that would use its sequencers, create large growth ...

Wolfe Research reiterated an Outperform rating and $150 price target on Illumina (ILMN) after Roche (RHHBY) presented scientific details about ...

RBC Capital reiterated an Outperform rating and $247 price target on Illumina (ILMN) after Roche (RHHBY) presented scientific details about its ...

Illumina is raising the curtain on its upcoming entry into spatial transcriptomics, with tech designed to help researchers ...

Set for release in 2026, the ‘first-of-its-kind’ technology aims to give researchers the ability to analyse more cells in a ...

Beijing’s surprise move to blacklist Illumina Inc. has unleashed a frenzy among the US firm’s Chinese rivals to win market share from the gene-sequencing giant.

‘Anaemic measure’ or a boost? In his Budget 2025 speech, Wong briefly touched on the ongoing stock market review. The main ...

Illumina is one of Mainboard-listed Venture Corporation’s major customers. Illumina’s shares have fallen some 26.4% over the ...

Illumina Inc (NASDAQ:ILMN)., a leading player in the genomic sequencing industry, finds itself at a critical juncture as it navigates a shifting competitive landscape and global economic challenges.

Market OverviewThe Global Carrier Screening Market is a genetic testing process that determines whether an individual carries ...

China has put Illumina on its ‘unreliable entity list’ after the US imposed sanctions on Beijing Genomics Institute, also a ...

Beijing’s action against clothing maker PVH and biotech company Illumina underlines risk created by trade tensions ...